03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10

Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09

Research, Mobility and commercialisation: ERA-MIND meeting on Mobility

Key issues in investing in People

Trieste, Italy, May 2010

2Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09

About a presenterAbout a presenter…… Frank HeemskerkFrank Heemskerk

Academic research (15 yr): Biomedical: NeuroscienceHOW does it work?Can we apply this to better therapies?

Utrecht (NL)Nat’l Inst Health (USA)UPasteur (FR)

But no tenure position...

many different grants and working with industrial partners ☺Personal -international- network !=>Joint decisions to move: dual careers !


Industry experience (13 yr): Biotech/pharma, Research Management, contracts, IPR, licensing, partnerships with academia, merger, multiple private investments

Moving to Belgium and into IndustryHow can we use joint knowledge to

develop better therapies?International Research Management: Biotech/Pharma, past-President EARMA RIMS bvba founder (2002), board member of several small companiesDeveloping global networks (2500)

How can we manage consortia?Develop and grow companies?Create socio-economic value together?

About a presenterAbout a presenter…… Frank HeemskerkFrank Heemskerk


Soft Skills:

- Networking !- Teamwork- Presentation skills !- Empathy- negotiation skills

Hard Skills:- scientific/technical knowledge acrossdisciplines- Project management- Time management- Budgeting


Possible barriers for discussion:Possible barriers for discussion:

1) personal level:Level of contacts: role of networksskill base: can be developed over timeFamily situation: dual careers, childres, etc

2) collaboration level:Is industry partner open for hosting?Strutcure of cooperation agreement (IPR, financial transfer, retention, long or short term contracts, one-one or network)Responsible partnering Guidelines, workshops, etc

3) national level:legal, financial/ tax and Social security Role of support/ service centres, job portals/ information servicesPR on role models in media and schools Allow flexibility in assignments (business people in education...?)


Recommendations for discussion:Recommendations for discussion:

1) e.g. Medicine vs Biotech, Chemistry - bad image, but we use products everyday =>PR actions, education, media => Visibility and basic understanding

2) multi-diciplinary teamwork, exchange with industry, projects, interactions between schools and industry !

3) Help those who want to take initiative:Helpdesks, mentoring schemes, portalsPR on role models in media and schools Stimulate networks, associations to help overcome barriersFlexible working conditions


Examples from practiseExamples from practise

Sharing goodpractices: successful interaction experiences between industry and academia


Where is the Value in joint R&D projects?Innovate products and processesFeed pipeline with new/ improved productsDiversify portfolio

Why invest now?: // current economic climateAccess to new knowledge, unique infrastructure, valuable materials, information dbasesAchieve critical mass (work faster/disseminate wider/ increase visibility) new experts (future staff?)

• Often SMEs drive innovation (products, services, new or niche markets)

• quite SMEs can be more flexible// react faster• Attract more public funding to lower risk

WHY invest in WHY invest in R&DR&D SMEs?SMEs?


Main Objectives: what do you want?Main Objectives: what do you want?What do you want to achieve?Innovate products and processes

Feed pipeline with new/ improved productsDiversify portfolioEnter new marketsenhance visibility

What do you want to avoid?:Loose competitive advantage (is always temporary !)loose key knowledgeLoose key expertsold infrastructureWork in isolation (influencing power)…


Project Management and Value chainProject Management and Value chain


ClinicalValid.

TargetID

LeadDiscovery

Regula-tory

Automated ChemicalSynthesis

Formulation

B2B Reagent Exchange

Formulation &Manufacturing

Clinical Validation

GlobalSubmission

Diagnostics &Monitoring

Patient Recruitment

Protocol Planning &Management

Dri-Science Technology

Chemi-informatics

Bioinformatics

Predictive Modeling

Hardware/ASP

HardwareInfrastructure

Network

Data Management

Privacy and Security

Predictive Modelingand Rational Design

Novel BiologicsDesign

Bioinformatics

Contract Discovery

HTS andCombi-Chem

Population Genomics DBs

Functional Genomics DBs

Genome Information Network

Toxicogenomics DBs

MetabonomicsDBs

“Due to the proliferation of information in the discovery space, the new R&D business model will evolve to virtual networks of coordinated service providers”

Virtual R&D

Source: Accenture Analysis, 2001


Academic Consulting, contract research Exchange Graduate studentsExchange of staff/ faculty

Collaborative Research projectsPatenting and licensing Spin-off

companies (JV, PPP, etc)

Service and out-reach Networking (critical mass)Policy recommendations

Transfer of knowledge: from academia to...:


- Ownership (who owns what) ?- Background/Foreground ?- Individual/ Institutional inventorship- (sub)contractor vs partner ?- Acces rights vs User Rights vs Commercialization ?- Co-development?- Financial Conditions (upfront, milestones, IP costs, royalty

structure) ?- Partners will have varied levels of experience and

expertise in Research management/ Knowledge Transfer practices

- Gaps between academics, entrepreneurs and investors: impact on collaborations, practices, need for training, professionalism

- International differences: financial, cultural and legal frameworks differ

Transfer of knowledge:


Market

Seed, BA,FFF Local VC Int’l VC IPO

Value

Perceived Risk

Research

Technol-CommercialIndustrialize

Cash needs

DevelopmentValidate Prototypes

Funding

Parallel Product Development

& Transfer at right moment

The Innovation Value chain:The Innovation Value chain:Risk perception and Risk perception and your Roleyour Role


rest of Society/ Government:

Industry

Academia

Investors

regulatoryethicallegalfiscal infrastructure education!understanding

cooperationexchange

Understandingmatching expectations


Knowledge triangle (FP7)Knowledge triangle (FP7)

Research

Education Innovation

Knowledge for Growth

New multidiscipl. challenges

skilled people,Services, products

Open Innovation, MobilityInnov in Educ,

new ideas

Knowledge, concepts

•Added value of an international network (new ideas)•Added value of international exploitation (new applications, mobility)•Critical mass (to fight fragmentation in Europe)

skilled people


1. Communication!2. Differences in management culture3. Partners will have varied levels of experience and

expertise in Research management/ Knowledge Transfer practices

4. Different timelines (days, years) and expectations (%, €)5. Lack of insight in business development6. Insufficient capacity (€, investment)7. Organizational capacity

PLUS: beware of International differences: financial, cultural and legal frameworks differ

Academia-Industry: Challenges


“Increasingly international R&D is done in a complex network environment: you need research management professionals to enable the different

players to act together”


M Curie Mobility project in chemical catalysis:Match 2 different academic groups in 2 countries + 1 SME

Idea 1 => invite 2 Fellows from across Europe to acquire knowledge for one year at both Universities + 1 fellow for research program in SMEIdea 2 => in second stage swap places: industrial fellow goes to academia and 2 academic fellows go to SMEVALUE:

Consortium to do Research + Development in parallelMatching expertise of 2 different academic fields with industrial requirementsUnique transfer of knowledge across borders and sectorsCenter of excellence for a very focused field with valuable industrial applicationsHigh level training events in specialist areaPossibly company growth (jobs) and leverage for investment (more €)

Project example:Project example:


large prenatal Diagnostics project:8 Hospitals : SP (2), BE, SLO, GK, CH, MEX

Research Institutes: UK (2)3 SMEs: SP, BE and MEX4 years, 6 M€

Problem: 1.8 million neonatal deaths/year, no early detection method;rate in MEX= 10x EU

Objectives: develop diagnostic test (proteomics) and tools (biomarkers) to detect high risk for miscarriagevalidate in clinical studies in MexicoTransfer knwoledge to Mexico for diagnostic business in LA

example Mexicoexample Mexico--Europe cooperation: 1Europe cooperation: 1

20weeks 12w screening

No Prevention

Preventive Interventions


Large Biofuel project:Universities: NL, AT, MEXResearch Institutes: MEX (2), SAfr, MozSMEs: BE, MEX, NL (3)3 years, 3.6 M€

Problem: Biofuel from food not sustainable, Mexican Jatropha palms can deliver high yield, but need to be optimizedObjectives:

select best species (from >300) and characterize (genomics, proteomics)Develop cultivation methods and Optimize oil extraction methods and other side productscreate business caseknowledge transfer between Europe, Mexico and Africa

example Mexicoexample Mexico--Europe cooperation: 2Europe cooperation: 2


Small M Curie Chair project:Top female specialist USA => Central European countryIdea => Chair at University + research program on HIV vaccine (Nanomedicine)

VALUE coming out: Develop larger Consortium to do world class R&DDevelop a Clinical trials vaccine cluster: building up specific expertiseCenter of excellence that is unique for Central-East Europe High level training events in specialist areasNow a spin-off company (jobs) + leverage for investment (private €)

Cluster example:Cluster example:


Cluster Strategic Product Development Plan:Cluster Strategic Product Development Plan:

© VTC ImmuneTherapy cluster

Transfer to othersTransfer to others

New ideas pipelineNew ideas pipeline

Build prototypesBuild prototypesTest with patients: safety+efficacyTest with patients: safety+efficacy


Create leverage (industry case):

Idea for proprietary HIV assay => patent + specific know how + unique proprietary dbase

1. Enables faster drug discovery progam (core) => attract investment 1 for drug development (Tibotec)

2. Enables Spin-off company for diagnostics=> short term revenue stream (Virco)

3. Enables to attract investment 2 for capacity development =>result: Real GROWTH

• Tibotec (started 1994) - Virco (started 1995)• 1998: 28 people• 2002: 250 people and acquired by Johnson& Johnson (500 M€)• 2009: 650 people and 2 drugs on the market

Company example: Flemish region of BelgiumCompany example: Flemish region of Belgium


PhenotypicPhenotypicDatabaseDatabase

GenotypicGenotypicDatabaseDatabase

Understanding HIV Drug resistance is the key Understanding HIV Drug resistance is the key to new drugs to new drugs

UHTS UHTS PhenotypingPhenotyping

Treatment monitoring

tools

New Drugs

BioinformaticsBioinformatics

GenomicsGenomics

Drug Targets

Pharmacogenomics enginePharmacogenomics engine

DrugDrugDiscovery & DevelopmentDiscovery & Development

PlatformsPlatforms


Knowledge

Strategy building

Experienced management

Research Development

Risk control

Shorter time to marketaccess to new markets

Innovation

Expert partnersConsortium building and public funding

Sufficient capacitySufficient private funding

Services

ProductsSuppliers


Research & Innovation Management Services bvbaDr Frank Heemskerk

E= [email protected]= +32 16 474092www.rimsinternational.eu

Thank you for your attention.

Further information:


1. Set internal rules (management decisions, IPR, communication, finance, infrastructure, publications, ...)

2. Create an environment open for collaboration

3. Allow a variety of funding streams

4. Think in processes: (R=>D=>solutions=>more R, etc)Research Mgngmt and Knowledge Transfer offices,but also professionalize support staff, students, etc

5. Communicate effectively to different stakeholders!

6. Innovate the Evaluation of staff, projects, outcomes: not just on # publications, but also on patents, quality of partnerships, socio-economic outcomes, risk, retention of key assets, etc

Recommendations:

03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10

Education

rims bvba brussels

academia dr frank heemskerk

conditions dr frank

industry partner

new knowledge

personal level

role models

national level